https://leerink.com/research/ 2026-07-01T13:06:49+00:00 https://leerink.com/research/healthcare-2018-outlook-alpha-opportunities-abound-in-healthcare-shares/ 2018-01-22T03:44:25+00:00 https://leerink.com/research/biotechnology-the-state-of-large-cap-biotech-2018-after-sfo-steady-as-she-goes/ 2018-01-31T03:42:46+00:00 https://leerink.com/research/a-site-visit-highlights-efforts-to-drive-value-to-customers-and-gain-market-share-outperform/ 2018-03-01T03:42:19+00:00 https://leerink.com/research/healthcare-facilities-selective-stock-picking-is-key-not-secular-volume-rebound-buy-hca-thc-uhs/ 2018-04-05T03:41:43+00:00 https://leerink.com/research/sien-a-come-back-story-in-the-making-resuming-coverage-with-outperform-19-price-target/ 2018-05-01T03:41:18+00:00 https://leerink.com/research/myl-focus-remains-on-key-product-catalysts-in-2018/ 2018-06-15T03:39:47+00:00 https://leerink.com/research/biotechnology-highlights-from-our-asco-kol-panel-on-lung-cancer-io-and-cell-therapies/ 2018-07-02T03:37:57+00:00 https://leerink.com/research/cvs-pbms-are-a-big-part-of-the-solution-rebate-capture-minimal/ 2018-08-31T03:36:46+00:00 https://leerink.com/research/jnj-leadership-series-growth-acceleration-with-strong-fcf-generation/ 2018-10-01T03:36:15+00:00 https://leerink.com/research/cll-survey-suggests-significant-opp-for-next-gen-btks-to-improve-on-imbruvica/ 2018-10-31T03:35:43+00:00 https://leerink.com/research/adms-using-drug-delivery-tech-to-make-better-drugs-initiating-adms-with-op/ 2018-11-30T03:34:27+00:00 https://leerink.com/research/healthcare-2019-outlook-macro-visibility-poor-its-a-stockpickers-year-in-healthcare/ 2019-01-02T03:33:58+00:00 https://leerink.com/research/hcit-shift-to-value-stronger-than-ever-according-to-klas-mdrx-still-challenged/ 2019-02-01T03:32:59+00:00 https://leerink.com/research/biotechnology-medacorp-hemophilia-survey-highlights-unmet-need-for-next-gen-disruptor-agents/ 2019-03-07T03:32:30+00:00 https://leerink.com/research/biotechnology-takeaways-from-the-svb-leerink-ghc-immuno-oncology-panel/ 2019-04-01T03:30:23+00:00 https://leerink.com/research/medical-devices-cardiology-u-s-tavr-survey-1q19-again-light-vs-street-points-to-in-line-sales-at-best/ 2019-04-30T03:29:49+00:00 https://leerink.com/research/biopharma-american-psychiatric-association-apa-2019-core-takeaways-and-industry-themes/ 2019-05-31T03:29:06+00:00 https://leerink.com/research/abbv-upgrading-the-new-cash-king-more-diversified-more-durable-cheaper-op-88-outperform/ 2019-07-01T17:22:48+00:00 https://leerink.com/research/biopharma-are-generic-deflation-trends-finally-starting-to-improve/ 2019-08-01T10:52:56+00:00 https://leerink.com/research/medical-supplies-and-devices-survey-highlights-market-share-gain-potential-is-real-for-spine-robotics-players/ 2019-08-29T10:52:37+00:00 https://leerink.com/research/regn-is-regn-becoming-the-tivo-of-biopharma-outperform/ 2019-10-01T23:17:37+00:00 https://leerink.com/research/life-science-tools-and-diagnostics-liquid-biopsy-insights-series-assessing-test-performance-and-technologies/ 2019-10-31T23:18:17+00:00 https://leerink.com/research/biopharma-highlights-from-svb-leerinks-polarxpress-bus-tour/ 2019-12-03T23:19:22+00:00 https://leerink.com/research/2020-outlook-for-investing-in-healthcare/ 2020-01-03T23:20:05+00:00 https://leerink.com/research/healthcare-is-covid-serology-antibody-testing-really-ready-for-the-big-reopening/ 2020-05-28T14:39:24+00:00 https://leerink.com/research/biopharma-immuno-oncology-tigit-pvrig-preview-heading-into-catalyst-rich-month/ 2020-06-01T19:35:36+00:00 https://leerink.com/research/gild-upgrading-to-op-94-pt-on-remdesivir-sales-arcus-and-other-pipeline-options-outperform/ 2020-07-01T15:45:45+00:00 https://leerink.com/research/covid-vaccine-series-1-competitive-landscape-timeline-and-what-to-expect/ 2020-08-04T17:14:27+00:00 https://leerink.com/research/it-aint-over-yet-covid-vax-timeline-uncertain-traditional-approach-preferred/ 2020-09-02T15:16:04+00:00 https://leerink.com/research/biopharma-cd20xcd3-smackdown-lets-get-ready-to-rumble/ 2020-10-01T14:18:16+00:00 https://leerink.com/research/life-science-tools-and-diagnostics-diving-deeper-into-multi-cancer-liquid-biopsy-screening-tests/ 2020-11-03T21:36:58+00:00 https://leerink.com/research/biopharma-covid-the-beginning-of-the-end-as-the-pieces-fall-into-place/ 2020-12-02T21:39:58+00:00 https://leerink.com/research/biopharma-vax-series-4-shibboleths-short-lived-immunity-vaccine-scarcity-local-mfg/ 2021-01-04T22:05:28+00:00 https://leerink.com/research/biopharma-biotech-financing-in-a-covid-year-record-deal-flow-record-capital-formation/ 2021-02-01T21:02:29+00:00 https://leerink.com/research/biopharma-2021-medacorp-ibd-physician-survey-shows-novel-orals-set-to-expand-market/ 2021-03-02T21:16:02+00:00 https://leerink.com/research/life-science-tools-and-diagnostics-volatility-creates-opportunities-highlighting-winners-among-the-crash-landing/ 2021-04-01T18:44:06+00:00 https://leerink.com/research/biopharma-three-dc-risks-that-could-keep-biopharma-multiples-depressed-all-year/ 2021-05-04T19:29:55+00:00 https://leerink.com/research/life-science-tools-and-diagnostics-comparing-performance-of-leading-mrd-liquid-biopsy-tests-as-early-data-emerges/ 2021-06-02T16:44:25+00:00 https://leerink.com/research/ntra-making-sense-of-the-signatera-adlt-increasing-estimates-pt-to-160-outperform/ 2021-07-01T13:37:44+00:00 https://leerink.com/research/vrtx-seen-this-movie-before-another-biopharma-multiple-compression-saga-pt-to-170-underperform/ 2021-08-03T14:13:09+00:00 https://leerink.com/research/ft516-ft596-in-nhl-give-4-strong-3-weak-and-5-uncertain-signals/ 2021-09-02T17:09:30+00:00 https://leerink.com/research/biopharma-immuno-oncology-round-up-from-esmo-2021/ 2021-10-01T17:13:30+00:00 https://leerink.com/research/healthcare-over-or-underreaction-svbl-analysts-on-molnupiravir-and-its-impact/ 2021-11-08T18:13:53+00:00 https://leerink.com/research/biopharma-flash-big-biopharma-will-have-500bn-in-gross-cash-to-deploy-ye22-get-set-for-ma/ 2022-01-05T19:40:33+00:00 https://leerink.com/research/healthcare-liquid-biopsy-nearing-the-finish-line-in-crc-screening-race/ 2022-02-01T16:04:06+00:00 https://leerink.com/research/biopharma-key-takeaways-from-ghc-panel-on-bispecifics-vs-cell-therapy-in-nhl-and-mm/ 2022-03-01T16:01:16+00:00 https://leerink.com/research/healthcare-providers-and-managed-care-home-health-more-downside-risk-to-ests-against-an-improving-operating-backdrop/ 2022-04-05T14:24:22+00:00 https://leerink.com/research/biopharma-tigit-clinical-updates-at-aacr-incrementally-positive/ 2022-05-02T14:21:38+00:00 https://leerink.com/research/biopharma-flash-tigit-disappoints-in-nsclc-numerical-improvement-leaves-some-hope/ 2022-06-01T20:21:18+00:00 https://leerink.com/research/mrk-flash-asco-checkpoint-round-up-early-stage-debates-and-io-io-outperform/ 2022-07-01T16:47:31+00:00 https://leerink.com/research/alny-raising-the-curtain-for-apollo-b-power-analysis-and-preview-market-perform/ 2022-08-01T21:20:40+00:00 https://leerink.com/research/biopharma-flash-pricing-policy-call-takeaways-updates-to-exposure-analysis/ 2022-09-01T15:00:40+00:00 https://leerink.com/research/biopharma-watchful-waiting-amyloid-hypothesis-at-stake-with-the-upcoming-ad-readouts/ 2022-10-03T21:39:56+00:00 https://leerink.com/research/healthcare-technology-distribution-2022-digital-health-innovators-disruptors-conference-takeaways/ 2022-11-01T21:40:32+00:00 https://leerink.com/research/biopharma-sitc-2022-io-development-and-regulatory-discussions/ 2022-11-19T17:26:58+00:00 https://leerink.com/research/mrk-flash-polarxpress-2022-takeaways-outperform/ 2022-12-07T15:58:43+00:00 https://leerink.com/research/biopharma-flash-takeaways-from-virtual-management-meetings-2023-day-0/ 2023-01-08T15:25:37+00:00 https://leerink.com/research/reta-if-approved-what-could-omavs-label-look-like-several-scenarios-possible-market-perform/ 2023-02-28T15:51:09+00:00 https://leerink.com/research/apples-oranges-and-the-first-of-many-bbio-bmrn-debates/ 2023-03-30T13:30:16+00:00 https://leerink.com/research/life-science-tools-and-diagnostics-foundations-of-discovery-drugs-dx-liquid-biopsy-panel-takeaways/ 2023-04-01T16:19:23+00:00 https://leerink.com/research/biopharma-chase-a-check-vol-3-biopharma-cash-runway-map/ 2023-05-01T13:25:36+00:00 https://leerink.com/research/biopharma-asco-single-agent-responses-with-io-but-context-matters-for-bolt-ipha-afmd/ 2023-06-01T13:43:45+00:00 https://leerink.com/research/biopharma-diversified-biopharmaceuticals-jnj-flash-oral-il-23-bid-efficacy-similar-to-stelara-but-below-injectable-il-23s-outperform/ 2023-07-01T14:40:30+00:00 https://leerink.com/research/biopharma-immuno-oncology-debates-questions-after-the-positive-os-trend-with-roches-tigit-in-sky-01/ 2023-08-25T14:19:12+00:00 https://leerink.com/research/biopharma-bullish-on-the-cah-opportunity/ 2023-09-30T14:39:10+00:00 https://leerink.com/research/biopharma-takeaways-from-our-pre-esmo-lung-cancer-pulse-call/ 2023-10-31T13:33:12+00:00 https://leerink.com/research/biopharma-emerging-large-biopharma-interest-in-cns/ 2023-11-30T14:31:15+00:00 https://leerink.com/research/biopharma-ash-anito-cel-ph-1-outcomes-are-strong-swings-in-expectations-pressure-aclx/ 2023-12-31T14:11:00+00:00 https://leerink.com/research/biopharma-beyond-incretins-evaluating-alternative-mechanisms-in-obesity/ 2024-02-28T13:53:38+00:00 https://leerink.com/research/healthcare-the-auto-cell-therapy-manufacturing-opportunity-lowering-cogs-driving-scale/ 2024-03-30T14:33:18+00:00 https://leerink.com/research/biopharma-will-aspen-send-it-or-huck-and-pray-previewing-big-brensocatib-binary-in-2q24/ 2024-05-10T11:12:06+00:00 https://leerink.com/research/biopharma-flash-not-to-be-alarmist-but-omicron-is-alarming-good-for-pfe-other-incumbents/ 2024-05-10T11:17:02+00:00 https://leerink.com/research/medacorp-alzheimers-panel-takeaways/ 2024-05-10T11:22:45+00:00 https://leerink.com/research/mersana-therapeutics-inc-time-2b-great-previewing-1h20-napi2b-data/ 2024-05-10T11:24:30+00:00 https://leerink.com/research/biopharma-immuno-oncology-aacr-2024-immuno-oncology-io-round-up/ 2024-05-17T17:05:00+00:00 https://leerink.com/research/biopharma-rare-diseases-crinetics-pharmaceuticals-inc/ 2024-06-04T18:49:37+00:00 https://leerink.com/research/biopharma-immunology-metabolism-live-from-eular-quick-takeaways-from-kyv-101-data-update/ 2024-07-11T12:15:40+00:00 https://leerink.com/wp-content/uploads/2024/07/Research-Hero_CMP_1170740969.jpg https://leerink.com/research/biopharma-takeaways-from-call-with-dr-scott-gottlieb/ 2024-09-04T17:34:46+00:00 https://leerink.com/research/biopharma-flash-new-analysis-a-closer-look-at-cms-prices-vs-existing-net/ 2024-10-31T12:12:26+00:00 https://leerink.com/research/healthcare-technology-and-distribution-managed-care-2025-stars-looks-potentially-challenged-on-cut-points/ 2024-10-31T12:13:25+00:00 https://leerink.com/research/next-ira-targets-whos-exposed-in-2027-2028/ 2024-11-01T13:47:05+00:00 https://leerink.com/research/hq-visit-highlights-reiterate-op/ 2024-12-02T15:58:55+00:00 https://leerink.com/research/test-results-are-in-prognosis-for-growth-looks-strong-initiate-op-pt-500/ 2025-01-14T14:15:46+00:00 https://leerink.com/research/landscape-of-multi-targeted-bispecifics-in-ii/ 2025-02-03T14:44:34+00:00 https://leerink.com/research/asco-gu-round-up/ 2025-03-03T14:48:06+00:00 https://leerink.com/research/tariff-risks-underappreciated-key-considerations-and-what-companies-are-saying/ 2025-04-01T13:41:43+00:00 https://leerink.com/research/very-concerning-fda-article/ 2025-05-01T14:30:33+00:00 https://leerink.com/research/previewing-trump-eo-mfn-exposure-quantified/ 2025-06-02T15:36:22+00:00 https://leerink.com/research/biopharma-chase-a-check-vol-7-biopharma-cash-runway-map-2023-2025/ 2025-07-01T20:25:56+00:00 https://leerink.com/research/abvx-ph3-abtect-induction-data-preview-a-key-value-inflecting-catalyst-for-abvx-outperform/ 2025-08-01T13:24:30+00:00 https://leerink.com/research/china-intensive-series-demystifying-diligence-of-chinese-biotechs/ 2025-09-02T13:54:19+00:00 https://leerink.com/research/eadv-2025-emerging-tx-recap-atopic-derm-hs-psoriasis-urticaria/ 2025-10-01T12:57:36+00:00 https://leerink.com/research/stat6-of-the-union-competitive-landscape-of-stat6-targeting-therapies/ 2025-11-03T14:02:40+00:00 https://leerink.com/research/biopharma-acr-2025-takeaways-cell-therapy-and-t-cell-engager-excitement-grows/ 2025-12-01T14:48:53+00:00 https://leerink.com/research/upcoming-vegfa-pd-l1-catalysts-next-3-4-months-could-be-a-wild-ride/ 2026-01-06T14:25:52+00:00 https://leerink.com/research/loe-cliffs-to-overcome-for-large-cap-biopharma/ 2026-02-02T13:42:48+00:00 https://leerink.com/research/paying-to-cut-the-line-at-fda-is-still-a-thing-a-look-at-prvs-and-their-value/ 2026-03-02T16:27:19+00:00 https://leerink.com/research/foundations-of-discovery-drugs-dx-key-takeawaysfrom-dx-ngs-panel/ 2026-04-06T19:26:32+00:00 https://leerink.com/research/crush-rfi-debate-ongoing-but-risks-appear-overblown-timing-unclear/ 2026-05-01T12:40:56+00:00 https://leerink.com/research/asco-more-room-for-smmt-bntx-upside-unlikely-w-higher-h-6-os-expectations/ 2026-06-01T12:20:29+00:00 https://leerink.com/research/life-science-tools-state-of-the-key-end-markets-the-outlook-ahead/ 2026-07-01T13:06:49+00:00